| Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing A Maynard, CE McCoach, JK Rotow, L Harris, F Haderk, DL Kerr, ... Cell 182 (5), 1232-1251. e22, 2020 | 436 | 2020 |
| Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo S Radhakrishnan, R Cabrera, EL Schenk, P Nava-Parada, MP Bell, ... The Journal of immunology 181 (5), 3137-3147, 2008 | 162 | 2008 |
| Targeting the complement pathway as a therapeutic strategy in lung cancer EK Kleczko, JW Kwak, EL Schenk, RA Nemenoff Frontiers in immunology 10, 954, 2019 | 109 | 2019 |
| Cancer cell–intrinsic expression of MHC class II regulates the immune microenvironment and response to anti–PD-1 therapy in lung adenocarcinoma AM Johnson, BL Bullock, AJ Neuwelt, JM Poczobutt, RE Kaspar, HY Li, ... The Journal of Immunology 204 (8), 2295-2307, 2020 | 87 | 2020 |
| LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid … SV Liu, LC Villaruz, VHF Lee, VW Zhu, CS Baik, A Sacher, CE McCoach, ... Annals of Oncology 31, S1189, 2020 | 75 | 2020 |
| Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro EL Schenk, BD Koh, KS Flatten, KL Peterson, D Parry, AD Hess, BD Smith, ... Clinical Cancer Research 18 (19), 5364-5373, 2012 | 72 | 2012 |
| A changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer JM Pacheco, DR Camidge, RC Doebele, E Schenk Frontiers in oncology 9, 195, 2019 | 57 | 2019 |
| Safety of influenza vaccine in patients with cancer receiving pembrolizumab JJ Failing, TP Ho, S Yadav, N Majithia, IB Riaz, JY Shin, EL Schenk, H Xie JCO oncology practice 16 (7), e573-e580, 2020 | 48 | 2020 |
| Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti–PD-1 response in NSCLC BL Bullock, AK Kimball, JM Poczobutt, AJ Neuwelt, HY Li, AM Johnson, ... Life science alliance 2 (3), 2019 | 48 | 2019 |
| HLA class I polymorphism has a dual impact on ligand binding and chaperone interaction WH Hildebrand, HR Turnquist, KR Prilliman, HD Hickman, EL Schenk, ... Human immunology 63 (4), 248-255, 2002 | 48 | 2002 |
| A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) versus placebo for patients with extensive-stage SCLC (ES SCLC) who were stable or responding … EL Schenk, SJ Mandrekar, GK Dy, MC Aubry, AD Tan, SR Dakhil, ... Journal of Thoracic Oncology 15 (1), 110-119, 2020 | 46 | 2020 |
| Disparate binding of chaperone proteins by HLA-A subtypes HR Turnquist, EL Schenk, MM McIlhaney, HD Hickman, WH Hildebrand, ... Immunogenetics 53, 830-834, 2002 | 38 | 2002 |
| The interface between tapasin and MHC class I: Identification of amino acid pesidues in both proteins that influence their interaction HR Turnquist, SE Vargas, EL Schenk, MM McIlhaney, AJ Reber, ... Immunologic research 25, 261-269, 2002 | 37 | 2002 |
| Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in stage IV non–small-cell lung cancer T Patil, R Mushtaq, S Marsh, C Azelby, M Pujara, KD Davies, DL Aisner, ... Clinical lung cancer 21 (3), e191-e204, 2020 | 35 | 2020 |
| Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO living guideline, version 2022.2 DH Owen, N Singh, N Ismaila, E Blanchard, P Celano, N Florez, D Jain, ... Journal of Clinical Oncology 41 (5), e10-e20, 2023 | 24 | 2023 |
| 2020 innovation‐based optimism for lung cancer outcomes EL Schenk, T Patil, J Pacheco, PA Bunn Jr The oncologist 26 (3), e454-e472, 2021 | 23 | 2021 |
| Retraction: Fast‐tracked CTL: Rapid induction of potent anti‐tumor killer T cells in situ KL Heckman, EL Schenk, S Radhakrishnan, KD Pavelko, MJ Hansen, ... European journal of immunology 37 (7), 1827-1835, 2007 | 20 | 2007 |
| Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer. JV Aredo, A Urisman, MA Gubens, C Mulvey, GM Allen, JK Rotow, ... Journal of Clinical Oncology 41 (16_suppl), 8508-8508, 2023 | 19 | 2023 |
| Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies E Schenk, AEW Hendrickson, D Northfelt, DO Toft, MM Ames, M Menefee, ... Investigational new drugs 31, 1251-1256, 2013 | 19 | 2013 |
| Clinical outcomes of patients on check point inhibitor therapy who receive routine vaccinations. EL Schenk Journal of Clinical Oncology 35 (15_suppl), e14597-e14597, 2017 | 16 | 2017 |
